Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Transgene
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France, Spain, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Cervical Cancer|Head and Neck Cancer|Oropharyngeal Cancer|Penile Cancer|Squamous Cell Carcinoma|Vaginal Cancer|Vulvar Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TG4001.12 | P2 |
Unknown Status |
Squamous Cell Carcinoma|Oropharyngeal Cancer|Cervical Cancer|Vaginal Cancer|Vulvar Cancer|Penile Cancer|Head and Neck Cancer |
2026-12-31 |
|
| TG4001.12 | P2 |
Active, not recruiting |
Squamous Cell Carcinoma|Cervical Cancer |
2024-12-01 |
23% |